Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

French reform piles the pressure on industry

This article was originally published in Scrip

Executive Summary

The reform proposals outlined by the French government look like a serious - and long overdue - attempt to improve transparency and patient safety, and to regain trust in drug regulation.

You may also be interested in...



Surveillance Data: The Key To Tackling AMR In Africa

A new project devised by Pfizer and the Wellcome Trust aims to tackle antimicrobial resistance (AMR) in four sub-Saharan African countries by using real world data to track resistance patterns and allow patients to be treated more successfully. Wellcome’s Gemma Buckland-Merrett explains how the project will work and how it could help other industry partners and governments to generate valuable data in the fight against AMR.

Coronavirus Notebook: New Nordic Studies, Vaccine Solidarity Pledges, And The Re-Start Of COPCOV

As the US snaps up most supplies of remdesivir, the EU says it is committed to ensuring global access to coronavirus medicines and international donors have been asked to pledge more money to pay for vaccines, medicines and tests. The past week has also seen some ups and downs for trials of various products for the treatment or prevention of COVID-19. 

EU Sees Drug Shortage Risk From COVID-19 Second Wave

A second wave of COVID-19 infection later this year would put even greater pressure on drugs used in patients hospitalized with serious respiratory problems, a new report warns.

Topics

UsernamePublicRestriction

Register

SC142496

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel